PDE4C stabilized by ELAVL1 promotes lymph node metastasis in papillary thyroid cancer

Area of Science:

• Oncology
• Molecular Biology
• Cancer Metastasis Research

Background:

• Lymph node metastasis (LNM) is critical for papillary thyroid carcinoma (PTC) recurrence.
• The role of Phosphodiesterase 4C (PDE4C) in PTC LNM requires further investigation.
• Identifying molecular drivers of PTC metastasis is essential for effective treatment strategies.

Purpose of the Study:

• To elucidate the functional role and molecular mechanism of PDE4C in PTC lymph node metastasis.
• To investigate the association between PDE4C and embryonic lethal abnormal vision like 1 (ELAVL1) in PTC.
• To evaluate the therapeutic potential of targeting PDE4C or ELAVL1 in PTC.

Main Methods:

• Bioinformatic analysis and immunohistochemistry (IHC) to assess PDE4C and ELAVL1 expression.
• Cell viability (CCK-8), migration, and invasion assays (Transwell) to evaluate PDE4C's functional role.
• RNA pull down, RNA immunoprecipitation (RIP), qRT-PCR, and Western blot to confirm ELAVL1-PDE4C interaction and expression.
• In vivo studies using xenograft models to assess the impact of PDE4C/ELAVL1 knockdown on tumor growth and metastasis.

Main Results:

• PDE4C and ELAVL1 were significantly upregulated in PTC tissues compared to normal tissues.
• Silencing PDE4C suppressed proliferation, migration, and invasion of PTC cell lines (BCPAP, TPC-1).
• ELAVL1 directly interacts with PDE4C mRNA, enhancing its stability and promoting malignant phenotypes.
• Knockdown of PDE4C or ELAVL1 inhibited PTC LNM, tumor growth, and Ki-67 expression in vivo.

Conclusions:

• ELAVL1 promotes lymph node metastasis in papillary thyroid carcinoma by increasing PDE4C mRNA stability.
• Targeting the ELAVL1-PDE4C axis represents a promising therapeutic strategy for inhibiting PTC metastasis.
• This study provides critical insights into the molecular mechanisms underlying PTC progression and metastasis.